(PRESS RELEASE) BENSENVILLE, IL — France-based Luneau Technology Group announced its merger with Optovue Inc, a privately held medical device company, headquartered in Fremont, California. Founded by Jay Wei in 2003, Optovue develops high-speed OCT and OCT-A technology to diagnose and manage eye diseases. Luneau Technology pioneered wavefront-based diagnostic and finishing solutions and led the development of highly automated solutions for the past 15 years.
A stronger global organization to drive vision care innovation
Dr. Marc Abitbol, CEO of Luneau Technology, will preside over the newly merged company, while Optovue CEO Peter Wyles will join the global leadership team. “It’s unprecedented what we will do together,” says Abitbol. “We’re two agile companies with a startup mentality of innovation and flexibility. Together, we now have a full pipeline that covers everything for visual health. Optovue’s OCT expertise, stellar reputation and primary position in the medical eye care market, and complementary portfolio of products, make us an ideal partner, so our combined company can offer complete end-to-end solutions in retail, refraction and medical markets for primary eye care.” The group has combined sales of $176 million, 700 employees in 120 countries, and offers a wide range of products. It sees tremendous growth opportunities in a market estimated to be worth $3 billion.
Emerging technologies to help Practitioners detect and manage eye health symptoms
With the largest ophthalmic market, North America is a primary focus of the new group. There are fewer than 700,000 eye care professionals in the world for a 7.2 billion population which means not enough professionals to take care of eye health problems, from refraction to diagnostics. This is where automated technologies from the combined group can help.
Right before this global release, Luneau Technology USA announced that its new Visionix VX650, an industry-first technology with multimodal anterior and posterior segment analysis, is now FDA-approved and available for sale in the United States. ECPs can experience the new product firsthand by requesting a live demo at Luneau Technology’s Vision Expo West booth or by scheduling a virtual demo with a Sales and Clinical Application Specialist. Later this year, Optovue will also be launching a new OCT-A screening device. “One technology will look at the front of the eye, like a camera, and the other the back of the eye so our technologies are very complementary,” Abitbol adds. These new technologies aim to transform and improve access to all patients in the United States and Canada, to help preserve their visual health. To learn more, visit luneautechusa.com and to watch Dr. Abitbol’s full interview.
Advertisement
